Previous studies exploring the predictive role of PD-L1 in melanoma patients treated with anti-PD-1 immunotherapy mainly measured its expression by tumor cells, or by tumor and immune cells without distinction [4,11,12,13,14], and did not evaluate the impact of immune cell expression separately. The gene discussed is CD274; the disease is neoplasm.